WebApr 21, 2014 · Financial policy of DR Reddy’s Laboratories Mar '13 Mar '12 Mar '11 Mar '10 Mar '09 financial policy debt assets ratio 0.16 0.18 0.19 0.086 0.1 Interest Cover 29.55 25.22 220.9 250.76 53.32 Debt Equity Ratio 0.50 0.65 0.59 0.39 0.57 11. 2013 Net Debt/Equity ratio: 0.20 In 2012 it is running high risk with debt ratios above 0.5, this … WebApr 14, 2024 · Summit Global Investments grew its position in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Get Rating) by 64.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC).The fund owned 18,369 shares of the company's stock after acquiring an additional 7,196 shares …
Bayer Pharma AG et al v. Dr. Reddy
WebPARTNERED BY Canara Robeco Blue Chip Equity Fund - Direct Plan (G) 3 Year Return: 25.52%. 5 Year Return: 14.59%. INVEST NOW. Equity Funds. PARTNERED … WebA Gx Pharma professional currently heading the financial planning and analytics (FP&A) function of Dr Reddy’s North America business, with nearly a decade of experience in the industry; adept at ... bar 20 ranch
Dr. Reddy’s Laboratories – Good Health Can’t Wait
Web16 minutes ago · Brightcom Group is asked to carry out the accounting impact of rectification of non-compliance. "BGL shall further ensure that the said statement of the impact of non-compliance is certified by a peer-reviewed chartered accountant (CA), other than the statutory auditor, who had audited at least one company forming part of NIFTY 100 or … WebDr. Reddy's Laboratories WebApr 13, 2024 · (Attachments: #1 Summons Issued Dr. Reddy's Laboratories, Ltd.)(jfm) April 13, 2024 Filing 6 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Johnson & Johnson for Janssen Pharmaceuticals, Inc. filed by Bayer AG, Bayer Pharma AG, Janssen Pharmaceuticals, Inc. (jfm) bar 2000 jaen